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be utilized in clinical practice. The analytic framework in this comparative effective-
ness analysis demonstrated the Coaguchek XS device to have a signiﬁcantly higher 
level of agreement with the core lab compared to the Hemochron device. This analysis 
led our institution to select the Coaguchek XS for use in our anticoagulation clinics 
on the basis of a superior quality and safety proﬁle.
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OBJECTIVES: To compare blood pressure (BP) goal achievement associated with the 
use of valsartan-based single pill combination (SPC) vs. ARB-based free combination 
(FC) among adult hypertension patients in South Central region (TX, AL, MS, LA, 
KS, TN, MO, AR & OK). METHODS: Data were collected from physician-adminis-
tered chart review of adult hypertension patients. All patients had uncontrolled BP 
before initiating one of the index therapies (SPC: valsartan+amlodipine or 
valsartan+HCTZ, FC: ARB+CCB or ARB+HCTZ) between 07/2008 and 06/2009. Up 
to 3 BPs were collected starting from 45 days after the therapy initiation. BP goal was 
<130/80 mmHg for patients with diabetes, chronic renal disease or coronary heart 
disease; or <140/90 mmHg for patients without these comorbidities. Kaplan-Meier 
method with log-rank test was used to compare rates of BP goal achievement associ-
ated with SPC vs. FC over time. Cox proportional hazard models were used to estimate 
the likelihood of BP goal achievement associated with SPC vs. FC, controlling for 
demographics, baseline BP, hypertension history, comorbidities, prior and concurrent 
use of anti-hypertensive medications, and physician specialty. RESULTS: The chart 
review included 813 patients: 415 on SPC (210 valsartan+amlodipine and 205 
valsartan+HCTZ) and 398 on FC (200 ARB+CCB and 198 ARB+HCTZ). In FCs, the 
most commonly used ARB and CCB were valsartan (29.1%) and amlodipine (81.5%), 
respectively. The rates of BP goal achievement were higher among SPC vs. FC patients 
over time (p = 0.007): 30.5% vs. 28.3% at month 3 and 63.4% vs. 53.8% at month 
6. Cox regression conﬁrmed that SPC patients were more likely to achieve BP goal 
(HR = 1.22; p = 0.047). Similar trend was observed in the subgroup analyses compar-
ing SPC valsartan+amlodipine vs. FC ARB+CCB and SPC valsartan+HCTZ vs. FC 
ARB+HCTZ separately. CONCLUSIONS: Patients using valsartan-based SPC were 
more likely to achieve BP goal than those treated with ARB-based FC.
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OBJECTIVES: Evidence-based guidelines for dyslipidemia therapy have provided 
deﬁnitive goals for low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) 
and suggested abnormal values for high-density lipoprotein cholesterol (HDL-C). The 
study objective was to determine lipid value attainment and dyslipidemia treatment 
rates. METHODS: Adult patients with two or more complete lipid panels from 
January 2005 through February 2009, regardless of dyslipidemia therapy, were identi-
ﬁed from the US nationally-representative HealthCore Integrated Research DatabaseTM 
(HIRD). Cardiovascular risk status was assigned based on National Cholesterol Edu-
cation Program (NCEP) criteria. Optimal lipid value (target) attainment was deﬁned 
using NCEP, American Heart Association, and American Diabetes Association crite-
ria. Target attainment for LDL-C, HDL-C and TG and lipid therapy treatment pat-
terns are described. RESULTS: A total of 227,903 patients were identiﬁed (mean 
follow-up = 1.9 years). At index lab, 21.1% of patients were at target for all three 
lipid fractions, 11.9% had no lipid fractions at target, 66.3% were at LDL-C target 
and 63.6% were not at target for either HDL-C or TG. Regardless of initial lipid 
fractions, only 28.7% of patients attained target over follow-up in all three lipid 
fractions. In patients with no lipid fractions at target at index, only 6.8% attained 
target for all lipid fractions and almost a third (31.9%) stayed at no lipid fractions at 
target; 44.4% of patients were receiving lipid-modifying therapy as of the last lipid 
lab (up from 33.0% at index), with twice as many on therapy attaining all targets 
versus no targets (66.6% vs. 29.0%). Statins were the most commonly used therapy 
(35.8%). CONCLUSIONS: Challenges to mixed dyslipidemia therapy still exist as 
evidenced by a minority of patients attaining optimal lipid values during the very 
recent timeframe of this study. These data may serve as valuable baseline benchmarks 
to evaluate the impact of new dyslipidemia guidelines and therapies.
PCV18
COST-UTILITY ANALYSIS OF TWO KINDS OF THERAPY FOR ACUTE 
ISCHEMIC STROKE
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OBJECTIVES: Mortality of Stroke in China is highest in the world, having brought 
a heavy ﬁnancial burden to society. And the number of acute Ischemic Stroke 
accounted for 75% of the total cases. This study wants to evaluate the treatment 
program to ﬁnd a better cost effectiveness treatment to offer reference for patients and 
clinicians choosing the right treatment. METHODS: A total of 145 cases with acute 
Ischemic Stroke during a period of 2007 −2008 admitted in 21 hospitals in China 
were divided randomly into two groups. One group of 69 patients was treated by 
Butylphthalide sodium chloride injection and Aspirin, another group of 66 patients 
were treated by Ozagrel injection and Aspirin. Two kinds of therapy were evaluated 
by double-blind, double-dummy trial from patients’ perspective. Utility of patients 
was investigated with EQ-5D.Direct costs were collected from HIS and questionnaires, 
indirect costs were estimated based on the opportunity cost of the time for caring and 
curing. Probabilistic sensitivity analysis using nonparametric Bootstrapping was done. 
RESULTS: From the EQ-5D score we can learn that the improved values of 
Butylphthalide group score during 8–14 days and 15–90 days are higher than that of 
Ozagrel group, the average cost per QALY (Quality-Adjusted Life-year) of a patient 
for Butylphthalide group (RMB 225,753.4) was lower, with RMB 11,706.3, than 
Ozagrel group (RMB 237,459.7), and incremental costs were RMB 451,710.5[95%CI, 
RMB 218,689.55–1080, 313.05]. The acceptability curve generated from the ICUR 
can be seen the possibility of Ozagrel group having the cost –effectiveness advantage 
is zero if the willingness to pay per QALY is lower than RMB 192,000.CONCLU-
SIONS: Switching from the current programmed to Butylphthalide group is more 
cost-effective as compared to Ozagrel group.
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OBJECTIVES: To evaluate the effectiveness of a comprehensive lipoprotein proﬁle 
(VAP) test coupled with an aggressive treatment protocol when compared to a stan-
dard lipid proﬁle test in patients with ischemic heart disease (IHD) or congestive heart 
failure (CHF). METHODS: All WellMed health plan enrollees with a diagnosis of 
IHD or CHF who had continuous enrollment between July 1, 2006 and June 30, 2008 
were identiﬁed. The case group (n = 1767) having at least one VAP test during this 
period was compared with the control group (n = 289) having no lipid testing or 
traditional lipid testing only. Univariate statistics were analyzed to describe the groups, 
and bivariate statistical tests (t-test or chi-square) examined differences between the 
two cohorts. RESULTS: Use of a treatment protocol in conjunction with a VAP test 
resulted in a signiﬁcant decrease in LDL (−6.64 mg/dL, <0.001) as well as an increase 
in HDL (3.95 mg/dL, <0.001). Individuals in the control group saw a signiﬁcant 
decrease in LDL (−6.14 mg/dL, 0.002) but did not see a signiﬁcant change in HDL 
(−1.21 mg/dL, 0.076). Combination drug therapy was more commonly used for cases 
when compared to controls (average drug types 2.1 vs. 1.8, 0.0004); particularly, the 
use of niacin containing products was considerably higher in the case group when 
compared to the control group (36% vs. 14.4%, <0.0001). Mean total costs in year 
1 ($4,308 vs. $5,141, 0.1157) and year 2 ($4,853 vs. $7,413, 0.0255) were lower for 
cases. CONCLUSIONS: Greater utilization of combination therapy guided by the 
VAP test appears to better manage IHD and CHF patients to NHLBI ATP III HDL 
and LDL targets than controls receiving usual care guided by traditional lipid testing. 
Advanced lipid proﬁle tests appear to offer clinicians better information about their 
patients’ lipid abnormalities when compared to traditional testing.
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OBJECTIVES: To examine the comparative effectiveness of heparin 5000 units given 
subcutaneously twice a day or three times a day, enoxaparin 30 mg given subcutane-
ously twice a day, and enoxaparin 40 mg given subcutaneously daily for the preven-
tion of venous thromboembolism in burn patients. METHODS: A retrospective cohort 
study was conducted by using the hospital claims database. All adult patients were 
included if they were admitted to Shands hospital between January 1, 1998 and 
September 30, 2008, had primary diagnoses of burn, and received either subcutaneous 
heparin or enoxaparin for VTE prophylaxis. The primary outcome was a VTE event, 
which was identiﬁed by using a previously validated ICD-9 coding algorithm and 
further conﬁrmed by chart review for radiographic evidence. RESULTS: A total of 
1111 patients were included. Seven patients (0.63%) experienced VTE events: 5 
(0.83%) received heparin, 1 (0.92%) received enoxaparin 30 mg, and 1 (0.25%) 
received enoxaparin 40 mg. There were no incidences of heparin-induced thrombocy-
topenia identiﬁed in any group. CONCLUSIONS: The VTE incidence is low in burn 
patients receiving pharmacological prophylaxis. Both heparin and enoxaparin appear 
to be equally effective in preventing VTE complications in this patient population.
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OBJECTIVES: To quantitatively assess the potential beneﬁts and harms of using 
reduced-function CYP2C19 genotype information to guide the use of the antiplatelet 
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agents clopidogrel and prasugrel. METHODS: We developed a decision model to 
evaluate the potential clinical beneﬁts and harms for three strategies—clopidigrel, 
prasugrel, and genotype-guided therapy—used for the treatment of patients with acute 
coronary syndromes with planned percutaneous coronary intervention. Data were 
derived from the published literature, including the TRITON-TIMI 38 trial, and 
publicly available sources. The lifetime incidence of clinical events was projected, and 
net health beneﬁt assessed using quality-adjusted life-years. Sensitivity and scenario 
analyses were conducted to assess uncertainty in results. RESULTS: Compared to 
clopidogrel therapy, prasugrel therapy was signiﬁcantly associated with an average 
incremental decrease in the lifetime risk of myocardial infarction, but also an average 
incremental increase in the risk of major bleed events and bleed deaths. The genotype-
guided treatment strategy did not exhibit any statistically signiﬁcant difference in the 
population risk of clinical events when compared to the clopidogrel and prasugrel 
strategies. No signiﬁcant differences in net beneﬁts were demonstrated among treat-
ment strategies. The nonvariant clopidogrel therapy population and the prasugrel 
therapy population had signiﬁcantly favorable cardiovascular and life expectancy 
outcomes compared to the CYP2C19 reduced-function allele population undergoing 
clopidogrel therapy. CONCLUSIONS: The inherent beneﬁt-harm tradeoff of anti-
platelet agents could potentially be improved with the use of CYP2C19 genotype 
information in patients with acute coronary syndrome. Genotype-guided therapy leads 
to improved outcomes for reduced-function CYP2C19 individuals, however this 
approach does not result in signiﬁcant differences for the aggregate acute coronary 
syndrome population when compared to the overall clopidogrel and prasugrel therapy 
strategies. Ongoing randomized controlled trials will be critical in further assessing 
the role of the CYP2C19 reduced function allele when deciding optimal antiplatelet 
treatment regimens.
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OBJECTIVES: The object of analysis is the presentation of results from the Heart-
Vessel Diseases Prophylactic Program for 40 and 50 year old residents of Wroclaw 
conducted from 1998 to 2008. 43 thousand people took part in the program. The 
aim of the program was to counteract health, life and disability risks which are among 
of the main causes of death in Poland—heart-vessel diseases as well as primary and 
secondary prevention and analysis of the appearance of the risk factors of these dis-
eases. METHODS: Outcomes analysis was used to evaluate the program. The analysis 
was carried out on the health results of two groups of participants of the program. 
The ﬁrst group comprised of 50 year old people invited to the program for the ﬁrst 
time. The second group comprised of the 50 year old participants who had already 
taken part in the program 10 years earlier. The participants of the program underwent 
health education concerning prophylactics of heart-vessel diseases and they were 
presented with coefﬁcients such as BMI, triglyceride levels, cholesterol, glucose and 
blood pressure. A health proﬁle was made for every participant. RESULTS: The health 
situation changed in almost 1/3 of the people in the group that took part in the 
program 10 years ago. The modiﬁable risk factors of heart vessel diseases underwent 
changes: an increase in protein intake (36%), increased physical activity (27%) as well 
as carrying out systematic blood sugar controls (22%).11% of the participants of the 
program, who were analyzed for the second time, thought that the health education 
carried out then, affected their life styles to a greater extent. CONCLUSIONS: After 
evaluation period of 10 years, efﬁciency of program and activities were analyzed and 
shown. Outcome analysis veriﬁed that 10 years of prophylactic program, reduced 
exposure to risk factor of DOTCS. We also selected an areas for future modiﬁcation 
and improvement. Due to outcomes analysis, regional politics of health protection 
was adequate to epidemiological factors and social needs of regions.
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OBJECTIVES: Coronary heart disease (CHD) mortality has declined substantially in 
Canada over recent decades. Our objective was to determine what proportion of this 
decline was associated with temporal trends in CHD risk factors and advancements in 
medical treatments. METHODS: The validated IMPACT model was used for all analy-
ses, integrating data on population size, CHD mortality, in addition to risk factor and 
treatment uptake changes in adults 25 years and older between 1994 and 2005 in 
Ontario. Relative risks and regression coefﬁcients from the published literature quanti-
ﬁed the relationship between CHD mortality and a) evidence-based therapies in 8 dis-
tinct CHD sub-populations (acute myocardial infarction (AMI), acute coronary 
syndromes, secondary prevention post-AMI, chronic angina/CHD, in-hospital, heart 
failure, community heart failure, and 1° prevention for hyperlipidemia or hypertension) 
and b) population trends in 6 risk factors (smoking, diabetes mellitus, systolic blood 
pressure, plasma cholesterol, exercise, and obesity). The outcome of interest was the 
number of deaths prevented or postponed. RESULTS: From 1994–2005, the age-
adjusted CHD mortality rate in Ontario fell 35% from 190.9 to 124.8 deaths per 
100,000 inhabitants, translating to an estimated 7585 fewer CHD deaths in 2005. 
Improvements in medical treatments accounted for approximately 43% of the total 
mortality decrease, most notably in AMI (9%), chronic angina (17%) and community 
heart failure (10%). Trends in risk factors explained approximately 48% % of the total 
mortality decrease, speciﬁcally reductions in plasma cholesterol (23%), and systolic 
blood pressure (20%). Increasing diabetes prevalence and body mass index had a nega-
tive impact, increasing CHD mortality by approximately 6% and 2%, respectively. 
CONCLUSIONS: Our results suggest that future CHD strategies should maximise 
evidence-based therapies and support more aggressive policies to promote healthy diets.
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OBJECTIVES: The purpose of this study was to evaluate the relative efﬁcacy and 
safety of dalteparin against anticoagulant therapies in patients with: cancer, medical 
patients at risk of VTE, total hip replacement, and acute myocardial infarction (AMI). 
METHODS: A meta-analysis was performed with randomized clinical trials (RCT) 
where anticoagulant therapies were used to prevent or treat VTE. Effectiveness was 
assessed with the reduction in pulmonary thromboembolism(PE) and deep vein throm-
bosis (DVT) events; safety with the frequency and type of adverse events(AE). RCT 
were searched in December 2008 in Medline, EMBASE and the Cochrane Collabora-
tion. Two independent reviewers identiﬁed the abstracts, selected the full articles and 
extracted data. Odds ratios and weighted means differences were calculated. Random 
effects models were employed in the analyses. RESULTS: From 2,539 abstracts, we 
obtained 91 RCT, 23 were excluded (unacceptable designs, insufﬁcient outcome data) 
leaving 68. Dalteparin(2500–7500 IU/day) was compared against unfractioned 
heparin, enoxaparin, warfarin, nadroparin, fondaparinux, aspirin and placebo. In 
patients with AMI, dalteparin showed to be effective in diminishing new infarctions 
and death (OR 0.66; 95%CI 0.33–0.99) or revascularizations (OR 0.76; 0.57–1.01). 
In total hip replacement patients, dalteparin showed reduction in DVT (OR 0.47; 
0.38–0.60) but not in PE (OR: 0.45; 0.09–2.39). In comparison to placebo, the 
number of deaths were lower (OR 0.14; 0.02–1.27). In patients with VTE no statistical 
differences were found against competing alternatives, as well as in thromboembolism, 
thrombosis progression and death. Finally, in cancer patients, dalteparin showed to 
be effective in diminishing DVT(OR 0.39; 0.22–0.68) but not differences in reducing 
mortality (OR 0.92; 0.73–1.17); major bleeding(OR 1.20; 0.48–2.98) or minor bleed-
ing (OR 0.87; 0.41–1.83). CONCLUSIONS: Dalteparin is an effective low-molecular-
weight heparin in the prevention and treatment of VTE in surgery and non surgery 
patients, not showing higher AE than unfractioned heparin or other recommended 
therapies.
PCV25
PERCUTANEOUS CORONARY INTERVENTION COMPARED WITH 
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VASCULAR CORONARY DISEASE
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OBJECTIVES: Diabetes patients with coronary artery disease represent a population 
with high cardiovascular morbidity and mortality. The objective of the study was to 
compare the long-term effectiveness of percutaneous coronary intervention (PCI) 
versus coronary artery bypass graft (CABG) in diabetic patients with multi-vascular 
coronary artery disease (MVD). METHODS: Studies were retrieved from PUBMED 
database using keywords: angioplasty, coronary, stent, PCI and coronary artery 
bypass surgery (August 1992 to December 2009). Randomised controlled trials which 
compared PCI and CABG in head to head comparisons were included according to 
pre-speciﬁed inclusion/exclusion criteria. The outcomes of interest were mortality, 
myocardial infarction (MI), stroke, and the use of additional revascularization proce-
dures. Two reviewers independently extracted data from the included studies. Data 
was analyzed using STATA (v9.0).RESULTS: Of the 416 studies identiﬁed, 5 studies 
met the inclusion criteria. A total of 813 patients were included in this analysis (208 
in ARTS, 78 in EARCI-II, 115 in MASS-II, 353 in BARI trial, and 59 in EAST). In 
total, 409 diabetic patients with MVD were randomized to PCI, and 404 were ran-
domized to CABG. Survival was signiﬁcantly greater after CABG than after PCI with 
a risk ratio of 1.28 (95% CI 1.06, 1.55); p = 0.009 for the ﬁve-year mortality rate. 
The relative risk for revascularization rate at ﬁve year follow-up was 4.11 (95% CI: 
2.20, 7.68) for PCI vs. CABG. Results for myocardial infarction were non-signiﬁcant 
with a risk ratio of 1.10 (95% CI: 0.73, 1.65); p = 0.644. CONCLUSIONS: CABG 
was associated with lower incidence of mortality and revascularization at ﬁve years 
of follow-up compared to PCI. Rate of MI was similar for both the procedures. 
Analysis from this review suggests that CABG greatly improves survival and re-
intervention rate when compared to PCI, in diabetic patients with multi-vessel coro-
nary artery disease.
